MAPT and tauopathy: The recently introduced second generation tau‐PET tracer 18F‐PI‐2620 has been shown to have affinity to 4R‐tau deposits as well as 3/4R‐tau in autoradiography and immunohistochemistry, together with an improved off‐target binding profile,9 suggesting suitability as a tau biomarker across primary and secondary tauopathies.